BIOAGE Labs Inc

NASDAQ:BIOAUnited States

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

other income 2,037 499 5,534 2,052 Loss from changes in fair value of warrants and derivative liabilities (306) (2,834) (384) (4,909) Loss on extinguishment of debt -- -- (250) -- --------- --------- --------- --------- Total other income (expense), net 1,343 (4,738) 2,852 (8,092) --------- --------- --------- --------- Net loss $ (23,407) $ (14,625) $ (49,980) $ (42,896) ========= ========= ========= ========= Net loss per share attributable to common stockholders, basic and diluted $ (6.70) $ (8.74) $ (21.76) $ (25.64) ========= ========= ========= ========= Weighted-average common shares outstanding, basic and dilutive 3,494,580 1,672,726 2,297,397 1,672,701 ========= ========= ========= ========= Comprehensive loss: Net loss (23,407) (14,625) (49,980) (42,896) Foreign currency translation adjustment 58 35 55 67 --------- --------- --------- --------- Total comprehensive loss $ (23,349) $ (14,590) $ (49,925) $ (42,829) ========= ========= ========= ========= BioAge Labs, Inc. Unaudited Condensed Consolidated Balance Sheets (In thousands) September 30, December 31, 2024 2023 --------------- -------------- Assets Current Assets: Cash and cash equivalents $ 334,474 $ 21,644 Restricted cash -- 3,313 Prepaid expenses and other current assets 1,993 349 ----------- ---------- Total current assets 336,467 25,306 ----------- ---------- Investments 100 100 Property and equipment, net 543 323 Operating right-of-use assets, net 271 195 ----------- ---------- Total assets $ 337,381 $ 25,924 =========== ========== Liabilities Current Liabilities: Accounts payable $ 2,098 $ 1,866 Accrued expenses and other current liabilities 10,709 7,938 Current portion of term loan 6,000 6,000 Operating lease liabilities, current 273 194 Convertible promissory notes -- 20,674 Convertible promissory notes embedded derivative liability -- 18,183 Deferred grant income -- 3,313 ----------- ---------- Total current liabilities 19,080 58,168 ----------- ---------- Term loan 3,940 8,201 Warrant liability 613 229 ----------- ---------- Total liabilities 23,633 66,598 =========== ========== Redeemable convertible preferred stock, par value of $0.00001, 31,634,362 shares authorized as of December 31, 2023, and 31,465,128 shares issued and outstanding as of December 31, 2023; aggregate liquidation preference of $131,864 as of December 31, 2023; no shares issued and outstanding as of September 30, 2024 -- 132,722 Commitments and Contingencies (Note 8) Stockholders' Equity (Deficit) Common stock, $0.00001 par value; 500,000,000 and 52,400,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 34,196,821 and 1,673,314 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively -- -- Preferred stock, $0.00001 par value; 10,000,000 shares authorized as of September 30, 2024; no shares issued and outstanding as of September 30, 2024; no shares authorized, issued, or outstanding as of December 31, 2023 -- -- Additional paid-in-capital 545,321 8,142 Accumulated other comprehensive income 109 164 Accumulated deficit (231,682) (181,702) ----------- ---------- Total stockholders' equity (deficit) 313,748 (173,396) ----------- ---------- Total liabilities and stockholders' equity (deficit) $ 337,381 $ 25,924 =========== ==========

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with azelaprag monotherapy